Generic Industry Not Sold On Benefits Of FDA Emerging Technology Program
Executive Summary
FDA’s calls for more generic industry participation in its Emerging Technology Program fell on deaf ears at recent meeting, with several complaining about the costs and value of investing in new manufacturing technologies.
You may also be interested in...
US FDA Sees Slow But Steady Progress In Adoption Of Continuous Manufacturing
The COVID-19 pandemic has prompted the ICH to delay by six months its efforts to develop Q13 guideline on continuous manufacturing, now not expected until May 2022.
US FDA Pharmaceutical Quality Office Lauds Continuous Manufacturing Approvals
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
FDA Continuous Manufacturing Guidance Raises Concerns About Scope And Cost
Makers of brand pharmaceuticals focused on scope issues and the definition of terms in their comments on the US FDA's draft continuous manufacturing guidance, while makers of generic drugs raised concerns about cost and lack of benefit.